Body · Medically-supervised weight loss
Wegovy (semaglutide)
A once-weekly prescription injection, dispensed by GPhC-registered pharmacy, supervised monthly.
What it is
Wegovy is the brand name for semaglutide, a once-weekly prescription injection licensed for chronic weight management in adults with obesity or excess weight with at least one weight-related health condition. It acts on the GLP-1 receptor to reduce appetite and slow gastric emptying.
Wegovy has been in use for weight management since 2021 and has a substantial real-world evidence base. In clinical trials (STEP-1), participants on the maintenance dose lost on average around 15% of their baseline body weight at 68 weeks.
What it treats
- Adults with a BMI ≥ 30
- Adults with a BMI ≥ 27 plus a weight-related health condition
How it works
- 1 Initial consultation with our prescriber.
- 2 If eligible, a starting dose of 0.25 mg once weekly is prescribed.
- 3 Dose titrates upward monthly — 0.5 mg, 1 mg, 1.7 mg, 2.4 mg — as tolerated.
- 4 Monthly review appointments.
- 5 Dispensed in a multi-dose pen by our partnered GPhC-registered pharmacy.
What to expect
Appointment time
Self-administered weekly injection at home. Monthly clinic review.
Downtime
None medically. First 2–3 weeks of each new dose may include nausea or reduced appetite.
How it feels
A small subcutaneous needle. Quick prick.
Aftercare
Inject the same day each week, vary site. Avoid heavy or fatty meals in the 24 hours after injection.
Results visible
From week 1–2 (appetite); month 2+ (visible weight loss)
How long they last
Ongoing while medication is appropriate
Is this right for you?
A good fit if
- You meet the prescribing criteria
- You're prepared to combine with diet and lifestyle changes
- You can commit to monthly review
Not the right time if
- You're pregnant, breastfeeding or planning to become pregnant
- You have a personal or family history of medullary thyroid cancer or MEN2
- You have a history of pancreatitis
Price
From £190 per month at the starting dose. Cost increases with dose.
Final price confirmed in your complimentary consultation. Cancellation policy.
FAQs
How does Wegovy compare to Mounjaro?
Mounjaro acts on two receptor pathways (GLP-1 and GIP) and has stronger weight-loss data in head-to-head trials. Wegovy has a longer track record in real-world use. Our prescriber will discuss which suits you.
How much weight will I lose?
Average results in trials are around 15% of body weight at 68 weeks on the maintenance dose. Real-world results vary widely depending on adherence and lifestyle.
Side effects?
Nausea, reduced appetite, constipation or loose stools, fatigue — most common in the first 2–3 weeks of any new dose, settle for most clients.
Is Wegovy available on the NHS?
In some circumstances, through specialist weight-management services. Most clients we see have either not met the NHS criteria, are on a long waiting list, or have chosen private supervision for the speed and convenience.
Related treatments
Mounjaro (tirzepatide)
Once-weekly GLP-1 / GIP injection — currently the strongest weight-loss data.
Learn more
Saxenda (liraglutide)
Once-daily GLP-1 injection — the longest-established option in this class.
Learn more
Medically-supervised weight loss
GLP-1 medications (Mounjaro, Wegovy, Saxenda) prescribed and supervised.
Learn moreReady when you are
Start with a complimentary consultation.
Thirty minutes, in person, at Knightsbridge or Harley Street. We'll listen, look, and tell you honestly what we'd recommend — and what we wouldn't.